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Acrocyanosis and digital necrosis, which caused by microangiopathic and immuno-
thrombosis phenomenon, may accompanied by microvascular involvement of other 
organs. Therefore, this finding can play a prognostic role in covid-19 outcome.
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1 |  INTRODUCTION
Coronavirus infection disease 2019 (COVID-19) may present 
with different symptoms and complications. Acrocyanosis 
and digital necrosis may be associated with COVID-19. We 
describe two patients with COVID-19 who died with acro-
cyanosis and digital necrosis at the terminal stage of their 
illness.
In the last days of 2019, severe acute respiratory syndrome 
coronavirus-2 (SARS-CoV-2) caused a disease in Wuhan, 
China, which was later named as coronavirus infection dis-
ease 2019 (COVID-19) and became a global health problem.1 
COVID-19 can present with mild flu-like to severe symptoms 
such as acute respiratory distress syndrome (ARDS), septic 
shock, poorly controlled metabolic acidosis, coagulation dys-
function, and multi-organ failure.2 Therefore, understanding 
specific and different symptoms and signs of the disease is of 
great importance. To the best of our knowledge, many of the 
symptoms and complications corresponded to the COVID-19 
are caused by cytokines and mediators of the immune sys-
tem induced by the infection. In this regard, cytokine storm 
is the result of the overproduction of major proinflammatory 
cytokines such as TNF-α, IL-6, and IL-1β that can produce 
hypercoagulable state and multiple organ dysfunction.3
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Similar to other types of ARDS, there is a hypercoagulable 
state in COVID-19 patients. This inflammatory condition, as a 
result of endovascular damage, increased platelet activity, and 
coagulation cascade causes the phenomenon of immunothrom-
bosis.4 Consequently, clot formation can be observed in large 
and small blood vessels, along with in situ pulmonary throm-
bosis and also thromboembolism (PTE).5 In other words, over-
activation of the coagulation pathway that occurs during the 
time of cytokine storm may be the result of increased thrombin 
activities. Furthermore, thrombin can play other roles in the in-
flammatory process by proteinase-activated receptors (PARs).3 
On the other hand, Yan Zhang et al reported antiphospholipid 
syndrome (APS) in COVID-19.6 Livedo reticularis, that also 
has been reported in COVID-19,7 is related to APS and cold 
agglutinin disease; accordingly, viral infection is one of the 
causes of cold agglutinin formation.8 Therefore, cold hem-
agglutinin disease should also be considered in patients with 
COVID-19 who present with this skin manifestation.
Furthermore, acrocyanosis has been described in critically 
ill patients with COVID-19 because of excessive coagulation 
status.9 Indeed, acrocyanosis and digital necrosis have pre-
viously been reported in many rheumatologic disorders and 
vasculitis, including ANCA-associated vasculitis, cryoglobu-
linemia vasculitis, lupus-related vasculitis, vasculopathy caused 
by APS, and also fingertips necrosis due to scleroderma vascu-
lar involvement as well as Raynaud's phenomenon.10-12 From 
a physiologic point of view, gangrene may occur by impaired 
blood flow and insufficient healing process of digital wounds 
which is associated with the increasing levels of C-reactive 
protein (CRP).11 Here, we describe two cases of critically ill 
patients with COVID-19 who developed digital acrocyanosis 
and subsequently fingertips necrosis during their illness.
2 |  CASE 1
A 56-year-old woman with diabetes referred to the emer-
gency department, with complaints of cough, headache, 
high-grade fever, dyspnea, and hypoxemia on April 
2020. Chest computed tomography (CT) showed bilat-
eral ground-glass opacities. Laboratory results revealed 
normal complete blood count, high CRP titer, and LDH 
(904 IU/L), while PT, INR, and PTT were in the normal 
range. Nasopharyngeal sampling was positive for SARS-
CoV-2 using real-time PCR method. Supplemental 
oxygen, prophylactic unfractionated heparin, and hy-
droxychloroquine were initiated. On day 5 of admis-
sion, she was intubated due to respiratory distress and 
sedative drugs were used to control the condition. On 
day 6, ecchymosis and patchy skin lesions appeared on 
her extremities. Owing to the probability of bacterial su-
perinfection, blood and tracheal secretion cultures were 
performed and meropenem and vancomycin were added 
to hydroxychloroquine. On day 7, she was transferred 
to designated COVID-19 center. At the admission, she 
was unconscious and still intubated under mechanical 
ventilation using SIMV + PS mode. The blood pressure 
and heart rate were 90/65  mm  Hg and 87/min, respec-
tively. Atrial blood gas (ABG) evaluation revealed that 
pO2 was 61 mm Hg and oxygen saturation was 90% with 
50% FIO2. Meanwhile, cyanosis was seen at the end of 
her upper and lower extremities, toes (Figure  1A), and 
fingers (Figure 1B), and spO2 with digital pulse oxime-
ter was about 87%. Blood sampling showed leukocyto-
sis (16  200  per  mm3), lymphopenia (1200  per  mm3), 
thrombocytopenia (91  000  per  mm3), Hb (7.8  g/L), 
high CRP titer (107 mg/L), LDH (1117  IU/L), D-dimer 
(7780 µg/mL), ferritin (1650 ng/mL), and IL-6 (359 pg/
mL). Additional laboratory findings indicated negative 
PANCA, CANCA, anticardiolipin, lupus anticoagulant, 
and β2-microglobulin. Echocardiographic was normal, 
while electrocardiogram showed inverted T in V1 to 
V5. Atorvastatin and aspirin were added to the treat-
ment regimen, and the dose of heparin was increased to 
the therapeutic dose. For improvement of blood flow on 
extremities, nitroglycerin ointment was also applied. In 
spite of the multiple treatment modalities, her clinical 
condition deteriorated and she ultimately demised.
F I G U R E  1  Acrocyanosis and gangrene 
of the toes (A) and fingers (B) are shown
(A) (B)
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3 |  CASE 2
A 67-year-old woman with a history of type II diabetes 
mellitus and systemic hypertension developed respiratory 
distress and was evaluated in the emergency department. 
Respiratory rate was 36/min, temperature 37.5°C and oxy-
gen saturation 65% on room air. Upon physical examina-
tion, coarse end-inspiratory crackles were noted at both 
lung bases. Chest X-ray showed bilateral airspace opaci-
ties, and diffuse ground-glass opacity was also found in 
spiral chest CT scan. Laboratory findings revealed leuko-
penia (4200 per mm3), lymphopenia (800 per mm3), normal 
platelet (160,000 per mm3) and hemoglobin level (13.7 g/
dL), high CRP (70 mg/L), LDH (840 IU/L), and D-dimer 
(976 µg/mL), whereas PT, INR, and PTT were in the nor-
mal ranges. Nasopharyngeal sampling was positive for 
SARS-CoV-2 using real-time PCR method. She required 
endotracheal intubation because of no response to oxygen 
therapy. Sedatives and neuromuscular blockade were used 
to enforce a lung-protective low-stretch strategy. Her treat-
ment was started with chloroquine 300 mg twice daily on 
the first day, followed by Lopinavir/ritonavir 400/100 mg 
twice daily. Other prescribed drugs included methylpredni-
solone, prophylactic unfractionated heparin, and antibiot-
ics. On 9th day of mechanical ventilation, in spite of the 
improvement in oxygenation and decrease of positive end-
expiratory pressure (PEEP) pressure, the patient developed 
terminal cyanosis in all fingers of her hands, and a lack 
of pulse in both radial arteries. Blood pressure decreased, 
and after initiating the therapeutic dose of heparin and fluid 
therapy, she had a radial artery pulse in the left hand with-
out any improvement in acrocyanosis. One day later, she 
developed subcutaneous emphysema in her chest, breasts, 
and face, and finally, passed away.
4 |  DISCUSSION
Acro-ischemia and cyanosis have been explained in critically 
ill patients with COVID-19 due to excessive coagulation sta-
tus.9 In addition, digital ischemia and necrosis may be ob-
served in other conditions such as diabetes mellitus or drug 
complications. In this regard, some critically ill patients may 
need norepinephrine for the treatment of hemodynamic im-
pairment in the ICU. In this condition, high-dose norepineph-
rine may be needed for circulatory shock, which can lead to 
more complications and poor outcomes. Accordingly, a pre-
vious history of peripheral vascular disease, hemodynamic 
disturbances, and prolonged hypotension that can be associ-
ated with concomitant use of other drugs such as dopamine 
may increase the risk of developing norepinephrine-induced 
digital necrosis.13 Although it is not clear that up to which 
dose norepinephrine is tolerable, the risk of impaired blood 
flow and digital necrosis increases when higher doses are ad-
ministered because of high vasoconstriction effect.13
Based on our findings and literature review, this is a mul-
tifactorial problem and various issues need to be considered 
the causes of this condition. Both of our patients suffered 
from type II diabetes mellitus, and diabetes mellitus is a pre-
disposing factor for ischemia and necrosis of extremities and 
digits. According to a report from China, the mortality rate 
was 7.3% in patients with COVID-19 who suffers from dia-
betes compared to the total mortality rate of 2.3% in normal 
population. It seems that diabetes and other associated co-
morbidities are aggravating factors for disease severity and 
complications.14 To the best of our knowledge, one of the 
most important long-term complications of diabetes is micro-
angiopathy, which causes damage to organs such as the eyes, 
kidneys, skin, and neurons. On the other hand, overexpression 
of some cytokines, for example, vascular endothelial growth 
factor (VEGF) and its receptor (VEGF-R) and the proscle-
rotic cytokine of transforming growth factor-β (TGF-β) play 
critical roles in angiogenesis and angiopathic transformation 
in these patients.15
Diabetic vasculopathy may be the reason for an impaired 
contribution of humoral immunity, and metabolic and he-
modynamic conditions.16 Further, complement-mediated 
thrombotic microangiopathies (TMA) have been reported in 
patients with COVID-19 that may be a concomitant problem 
in these patients.17 With this respect, microvascular involve-
ment such as inflammatory accumulation of neutrophils and 
platelets and intravascular fibrin deposition have been also 
reported in autopsy studies.18 Consequently, the occurrence 
of these risk factors may worsen the disease and complica-
tions may be aggravated. Therefore, it is vital to take them 
into consideration.
In our patients, based on the ECG changes and hemody-
namics findings, it seems that acrocyanosis and digital necro-
sis may be accompanied by vascular and thrombotic events 
in other organs but there was not enough time for systemic 
vascular evaluation by Doppler examination to confirm these 
hypotheses owing to the critical condition of the patients. We 
noticed that none of our patients received vasoactive drugs 
in the course of their disease, and in case of receiving a va-
sopressor, drug side effects might be an additive factor for 
digital necrosis. The presence of acrocyanosis in patients 
with COVID-19 can indicate organ damage due to vascu-
lar involvement and is a sign of the severity of the disease. 
Acrocyanosis can play a prognostic role and demonstrate 
poor outcomes in these patients. We recommend changing 
the prophylactic dose to intermediate or therapeutic dose of 
anticoagulant drugs, possibly plus adequate vasodilator ther-
apy, if the patient presented with acrocyanosis. According to 
the recent study, catecholamines may play a role in increasing 
cytokines such as IL-6,19 which can aggravate the complica-
tions of COVID-19.
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In conclusion, some important risk factors that increase 
the chances of microangiopathy and vascular disorders should 
be considered in critically ill patients with COVID-19. These 
items include diabetes mellitus, smoking, a history of athero-
sclerosis, and high plasma levels of CPR, IL-6, D-dimer, and 
fibrinogen. Moreover, the administration of noradrenaline 
may be a risk factor for causing acrocyanosis, digital necro-
sis, and cytokine release via IL-6 production.
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